Over the past 20 years, high-risk human papilloma-virus (HPV) infection has been established as a risk factor for developing head and neck squamous cell carcinoma, independent of tobacco and alcohol use. In particular, HPV is strongly associated with the development of oropharyngeal cancer and a small minority of oral cavity cancers. In this review, we summarize what is currently known about the biology of HPV, the mechanisms by which it effects malignant transformation, and the potential impact of HPV status on the clinical management of persons with head and neck cancer.
Get full access to this article
View all access options for this article.
References
1.
Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. -1995-. High incidence of p53 alterations -mutation, deletion, overexpression- in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene10:1217–1227.
2.
Andrews E, Seaman WT, Webster-Cyriaque J -2008-. Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. Oral Oncol -in press-.
3.
Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks GD, et al. -1991-. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol65:2254–2260.
4.
Begum S, Cao D, Gillison M, Zahurak M, Westra WH -2005-. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res11:5694–5699.
5.
Begum S, Gillison ML, Nicol TL, Westra WH -2007-. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res13:1186–1191.
6.
Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, et al. -2000-. “High risk” HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol13:644–653.
7.
Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, et al. -2004-. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst96:998–1006.
8.
Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F -1996-. Cellular responses of HPV-positive cancer cells to genotoxic anti- cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer68:506–513.
9.
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. -1996-. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res56:2488–2492.
10.
Canto MT, Devesa SS -2002-. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol38:610–617.
11.
Carlos de Vicente J, Junquera Gutierrez LM, Zapatero AH, Fresno Forcelledo MF, Hernandez-Vallejo G, Lopez Arranz JS -2004-. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck26:22–30.
12.
Chang F, Syrjänen S, Kellokoski J, Syrjänen K -1991-. Human papillomavirus -HPV- infections and their associations with oral disease. J Oral Pathol Med20:305–317.
13.
Charfi L, Jouffroy T, de Cremoux P, Le Peltier N, Thioux M, Freneaux P, et al. -2008-. Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. Cancer Lett260:72–78.
14.
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML -2008-. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol26:612–619.
15.
Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT -1995-. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev9:2335–2349.
16.
Chuang AY, Chuang TC, Chang S, Zhou S, Begum S, Westra WH, et al. -2008-. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol44:915–919.
17.
Crook T, Morgenstern JP, Crawford L, Banks L -1989-. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J8:513–519.
18.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. -2007-. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med356:1944–1956.
19.
El-Mofty SK, Lu DW -2003-. Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol27:1463–1470.
20.
Ernster JA, Sciotto CG, O‘Brien MM, Finch JL, Robinson LJ, Willson T, et al. -2007-. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope117:2115–2128.
21.
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. -2008-. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst100:261–269.
22.
Fouret P, Martin F, Flahault A, Saint-Guily JL -1995-. Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Diagn Mol Pathol4:122–127.
23.
Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM -1996-. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev5:567–575.
24.
Friesland S, Mellin H, Munck-Wikland E, Nilsson A, Lindholm J, Dalianis T, et al. -2001-. Human papilloma virus -HPV- and p53 immunostaining in advanced tonsillar carcinoma—relation to radiotherapy response and survival. Anticancer Res21-1B-:529–534.
25.
Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, et al. -2007-. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer120:2386–2392.
26.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. -2000-. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst92:709–720.
27.
Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. -2008-. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst100:407–420.
28.
Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, et al. -2008-. Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck30:898–903.
29.
Greer RO Jr, Eversole LR, Crosby LK -1990-. Detection of human papillomavirus-genomic DNA in oral epithelial dysplasias, oral smokeless tobacco-associated leukoplakias, and epithelial malignancies. J Oral Maxillofac Surg48:1201–1205.
30.
Ha PK, Pai SI, Westra WH, Gillison ML, Tong BC, Sidransky D, et al. -2002-. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res8:1203–1209.
31.
Ha PK, Benoit NE, Yochem R, Sciubba J, Zahurak M, Sidransky D, et al. -2003-. A transcriptional progression model for head and neck cancer. Clin Cancer Res9:3058–3064.
32.
Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, Ramaekers FC, et al. -2003-. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8. Int J Cancer107:394–400.
33.
Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, Schildt EB, Bladstrom A, et al. -2005-. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol125:1337–1344.
34.
Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G -1996-. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol16:859–867.
35.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. -2004-. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364:1757–1765.
36.
Hemminki K, Dong C, Frisch M -2000-. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev9:433–437.
37.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. -1995-. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res55:4525–4530.
38.
Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. -2003-. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst95:1772–1783.
39.
Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ -2006-. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol31:259–266.
40.
Holladay EB, Gerald WL -1993-. Viral gene detection in oral neoplasms using the polymerase chain reaction. Am J Clin Pathol100:36–40.
41.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. -2008-. Cancer statistics, 2008. CA Cancer J Clin58:71–96.
42.
Kim SH, Koo BS, Kang S, Park K, Kim H, Lee KR, et al. -2007-. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer120:1418–1425.
43.
Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, et al. -2003-. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol162:747–753.
44.
Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, et al. -2004-. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis189:686–698.
45.
Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, et al. -2007-. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys69-2 Suppl-:109S–111S.
46.
Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. -2008-. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol26:3128–3137.
47.
Li W, Thompson CH, O’Brien CJ, McNeil EB, Scolyer RA, Cossart YE, et al. -2003-. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer106:553–558.
48.
Li Y, Nichols MA, Shay JW, Xiong Y -1994-. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res54:6078–6082.
49.
Liang XH, Lewis J, Foote R, Smith D, Kademani D -2008-. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg66:1875–1880.
50.
Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, et al. -2006-. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol24:5630–5636.
51.
Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM -2001-. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer92: 805–813.
52.
Longworth MS, Laimins LA -2004-. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev68:362–372.
53.
Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L, Beckmann AM -1996-. Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Int J Cancer69:152–158.
54.
Matzow T, Boysen M, Kalantari M, Johansson B, Hagmar B -1998-. Low detection rate of HPV in oral and laryngeal carcinomas. Acta Oncol37:73–76.
55.
McDougall JK -1994-. Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol186:101–119.
56.
McLaughlin-Drubin ME, Bromberg-White JL, Meyers C -2005-. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology338:61–68.
57.
Miguel RE, Villa LL, Cordeiro AC, Prado JC, Sobrinho JS, Kowalski LP -1998-. Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg176: 428–429.
58.
Miller CS, White DK -1996-. Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod82:57–68.
59.
Mork J, Lie AK, Glattre E, Clark S, Hallmans G, Jellum E, et al. -2001-. Human papillomavirus infection as a risk factor for squamouscell carcinoma of the head and neck. N Engl J Med344:1125–1131.
60.
Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM -1989-. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J8:4099–4105.
61.
Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. -2004-. Mechanisms of human papillomavirus-induced oncogenesis. J Virol78:11451–11460.
62.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. -2003-. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med348:518–527.
63.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. -2007-. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet369:2161–2170; erratum in Lancet 370:1414, 2007.
64.
Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, et al. -2006-. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res12:6643–6651; erratum in Clin Cancer Res 13:4313, 2007.
65.
Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F, et al. -2006-. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer95:1432–1438.
66.
Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. -1996-. High frequency of p16 -CDKN2/MTS-1/INK4A- inactivation in head and neck squamous cell carcinoma. Cancer Res56:3630–3633.
67.
Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, et al. -2007-. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer120:1731–1738.
68.
Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, et al. -2003-. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer104:336–344.
69.
Rose Ragin CC, Taioli E -2008-. Second primary head and neck tumor risk in patients with cervical cancer—SEER data analysis. Head Neck30: 58–66.
70.
Sand L, Jalouli J, Larsson PA, Hirsch JM -2000-. Human papilloma viruses in oral lesions. Anticancer Res20-2B-:1183–1188.
71.
Scheffner M, Whitaker NJ -2003-. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol13: 59–67.
72.
Scheffner M, Munger K, Huibregtse JM, Howley PM -1992-. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J11:2425–2431.
73.
Schmalbach CE, Miller FR -2007-. Occult primary head and neck carcinoma. Curr Oncol Rep9:139–146.
74.
Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, et al. -1998-. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst90:1626–1636.
75.
Serrano M, Hannon GJ, Beach D -1993-. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature366:704–707.
76.
Shiboski CH, Schmidt BL, Jordan RC -2005-. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer103:1843–1849.
77.
Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR -2002-. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck24:841–849.
78.
Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, et al. -2006-. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene25:2558–2564.
79.
Snijders PJ, van den Brule AJ, Meijer CJ -2003-. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol201:1–6.
80.
Stubenrauch F, Laimins LA -1999-. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol9:379–386.
81.
Sturgis EM, Cinciripini PM -2007-. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer110:1429–1435.
82.
Syrjänen S -2005-. Human papillomavirus -HPV- in head and neck cancer. J Clin Virol32-Suppl 1-:59–66.
83.
Villa LL -2006-. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine24-Suppl 1-:23–28.
84.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. -1999-. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol189:12–19.
85.
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. -2006-. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol24:736–747.
86.
Werness BA, Levine AJ, Howley PM -1990-. Association of human papilloma-virus types 16 and 18 E6 proteins with p53. Science248-4951-: 76–79.
87.
White AE, Livanos EM, Tlsty TD -1994-. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev8:666–677.
88.
Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX -2002-. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene21:1510–1517.
89.
Wilczynski SP, Lin BT, Xie Y, Paz IB -1998-. Detection of human papillo-mavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol152:145–156.
90.
Wong RJ -2008-. Current status of FDG-PET for head and neck cancer. J Surg Oncol97:649–652.
91.
Worsham MJ, Chen KM, Tiwari N, Pals G, Schouten JP, Sethi S, et al. -2006-. Fine-mapping loss of gene architecture at the CDKN2B -p15INK4b-, CDKN2A -p14ARF, p16INK4a-, and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg132:409–415.
92.
Zhang MQ, El-Mofty SK, Davila RM -2008-. Detection of human papillo-mavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer114:118–123.
93.
zur Hausen H -2000-. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst92: 690–698.
